Structure of Ispinesib
CAS No.: 336113-53-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Ispinesib is a quinazolinone-derived, specific and reversible kinesin spindle protein inhibitor with Kiapp value of 1.7 nM.
Synonyms: SB-715992; CK0238273
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 336113-53-2 |
Formula : | C30H33ClN4O2 |
M.W : | 517.06 |
SMILES Code : | O=C(N(CCCN)[C@@H](C(N1CC2=CC=CC=C2)=NC3=C(C=CC(Cl)=C3)C1=O)C(C)C)C4=CC=C(C)C=C4 |
Synonyms : |
SB-715992; CK0238273
|
MDL No. : | MFCD22628831 |
InChI Key : | QJZRFPJCWMNVAV-HHHXNRCGSA-N |
Pubchem ID : | 6851740 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
K562 cells | 100 nM | To assess the inhibitory effects on cancer cell lines. | PMC3428805 | |
HeLa cells | 1 nM | 72 hours | To evaluate the inhibitory effect of Ispinesib on HeLa cell proliferation, results showed that Ispinesib synergistically inhibited cell proliferation with KIF15-IN-1. | PMC5960320 |
HCT116 cells | 50 – 125 nM | two to four weeks | To select resistant clones and analyze their resistance mechanisms | PMC4123312 |
HeLa cells | 10 nM to 100 nM | 10 days | To validate the A133P mutation's resistance to Ispinesib via CRISPR/Cas9 genome editing | PMC4123312 |
MDA-MB-468 cells | 150 mM | 48 hours | To evaluate the cell cycle and apoptotic responses of MDA-MB-468 cells to Ispinesib, results showed cell cycle arrest at M phase and induction of apoptosis. | PMC2844774 |
BT-474 cells | 150 mM | 48 hours | To evaluate the cell cycle and apoptotic responses of BT-474 cells to Ispinesib, results showed transient cell cycle arrest at M phase followed by re-entry into interphase. | PMC2844774 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | Breast cancer xenograft models | Intraperitoneal injection | 10 mg/kg or 8 mg/kg | Every 4 days for 3 doses | To evaluate the antitumor activity of Ispinesib in breast cancer xenograft models, results showed tumor regression in all models, with complete regression in some models. | PMC2844774 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00169520 | Solid Tumor Cancer | Phase 1 | Completed | - | United Kingdom ... More >> GSK Investigational Site Oxford, Oxfordshire, United Kingdom, OX2 6PD GSK Investigational Site London, United Kingdom, SW3 6JJ Less << |
NCT00607841 | Breast Neoplasms | Phase 1 Phase 2 | Completed | - | Peru ... More >> Hospital Nacional Alberto Sabogal Sologúren Lima, Peru Hospital Nacional Edgardo Rebagliati Martins Lima, Peru Instituto Nacional de Enfermedades Neoplásicas Lima, Peru Less << |
NCT00103311 | - | Completed | - | - | |
NCT00103311 | Recurrent Colon Cancer ... More >> Recurrent Rectal Cancer Stage IIIA Colon Cancer Stage IIIA Rectal Cancer Stage IIIB Colon Cancer Stage IIIB Rectal Cancer Stage IIIC Colon Cancer Stage IIIC Rectal Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer Less << | Phase 2 | Completed | - | United States, California ... More >> University of Southern California, Norris Los Angeles, California, United States, 90033 Less << |
NCT00085813 | Non-Small-Cell Lung Cancer | PHASE2 | COMPLETED | 2025-10-05 | GSK Investigational Site, Scot... More >>tsdale, Arizona, 85259, United States|GSK Investigational Site, Jacksonville, Florida, 32224, United States|GSK Investigational Site, Rochester, Minnesota, 55905, United States|GSK Investigational Site, Rochester, New York, 14623, United States|GSK Investigational Site, Greensboro, North Carolina, 27403, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19111, United States|GSK Investigational Site, Memphis, Tennessee, 38104, United States|GSK Investigational Site, Bruxelles, 1000, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Sutton, Surrey, SM2 5PT, United Kingdom Less << |
NCT00095953 | Melanoma (Skin) | Phase 2 | Completed | - | Canada, British Columbia ... More >> British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 Fraser Valley Cancer Centre at British Columbia Cancer Agency Surrey, British Columbia, Canada, V3V 1Z2 British Columbia Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Nova Scotia Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Canada, Quebec Centre Hospitalier de l'Universite de Montreal Montreal, Quebec, Canada, H2L-4M1 Less << |
NCT00101244 | Adult Grade III Lymphomatoid G... More >>ranulomatosis Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Splenic Marginal Zone Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Small Lymphocytic Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Waldenstr?m Macroglobulinemia Less << | Phase 1 | Terminated(Administratively Co... More >>mplete.) Less << | - | United States, Michigan ... More >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Less << |
NCT00096499 | Adenocarcinoma of the Prostate... More >> Recurrent Prostate Cancer Stage IV Prostate Cancer Less << | Phase 2 | Completed | - | United States, Texas ... More >> Southwest Oncology Group San Antonio, Texas, United States, 78245 Less << |
NCT00097409 | Ovarian Cancer | PHASE2 | COMPLETED | 2025-05-07 | GSK Investigational Site, Birm... More >>ingham, Alabama, 35205, United States|GSK Investigational Site, New Orleans, Louisiana, 70115, United States|GSK Investigational Site, St. Louis, Missouri, 63110, United States|GSK Investigational Site, Mayfield Heights, Ohio, 44124, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73104, United States|GSK Investigational Site, Abington, Pennsylvania, 19001-3788, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Seattle, Washington, 98101, United States|GSK Investigational Site, Madison, Wisconsin, 53792, United States Less << |
NCT00095992 | Liver Cancer | Phase 2 | Completed | - | Canada, British Columbia ... More >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00136578 | Solid Tumours | Phase 1 | Completed | - | United States, Tennessee ... More >> GSK Investigational Site Nashville, Tennessee, United States, 37203 United Kingdom GSK Investigational Site Newcastle Upon Tyne, Northumberland, United Kingdom, NE4 6BE Less << |
NCT00098826 | Acute Undifferentiated Leukemi... More >>a Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia de Novo Myelodysplastic Syndromes Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Refractory Anemia With Excess Blasts Refractory Anemia With Excess Blasts in Transformation Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Untreated Adult Acute Myeloid Leukemia Less << | Phase 1 | Completed | - | United States, Ohio ... More >> Case Western Reserve University Cleveland, Ohio, United States, 44106 Less << |
NCT00363272 | Childhood Burkitt Lymphoma ... More >> Childhood Central Nervous System Germ Cell Tumor Childhood Choroid Plexus Tumor Childhood Craniopharyngioma Childhood Grade I Meningioma Childhood Grade II Meningioma Childhood Grade III Meningioma Childhood High-grade Cerebral Astrocytoma Childhood Infratentorial Ependymoma Childhood Low-grade Cerebral Astrocytoma Childhood Spinal Cord Neoplasm Childhood Supratentorial Ependymoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Brain Tumor Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Grade III Lymphomatoid Granulomatosis Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Medulloblastoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway and Hypothalamic Glioma Unspecified Childhood Solid Tumor, Protocol Specific Less << | Phase 1 | Completed | - | United States, California ... More >> Children's Oncology Group Arcadia, California, United States, 91006-3776 Less << |
NCT00095628 | Metastatic Squamous Neck Cance... More >>r With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Stage IVA Salivary Gland Cancer Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVB Salivary Gland Cancer Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Salivary Gland Cancer Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Less << | Phase 2 | Completed | - | Canada, Ontario ... More >> Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00095628 | - | Completed | - | - | |
NCT00089973 | Neoplasms, Breast | PHASE2 | COMPLETED | 2006-08-25 | GSK Investigational Site, Jack... More >>sonville, Florida, 32224, United States|GSK Investigational Site, Indianapolis, Indiana, 46202, United States|GSK Investigational Site, Chapel Hill, North Carolina, 27599, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15213, United States|GSK Investigational Site, Bruxelles, 1000, Belgium|GSK Investigational Site, Bandar Tun Razak, Cheras, 56000, Malaysia|GSK Investigational Site, Bandar Tun Razak, Cheras, 59100, Malaysia|GSK Investigational Site, Singapore, 119074, Singapore|GSK Investigational Site, Singapore, 169610, Singapore|GSK Investigational Site, Southampton, Hampshire, SO16 6YD, United Kingdom|GSK Investigational Site, Manchester, Lancashire, M20 4BX, United Kingdom|GSK Investigational Site, Newcastle Upon Tyne, Northumberland, NE4 6BE, United Kingdom|GSK Investigational Site, London, W12 0NN, United Kingdom Less << |
NCT00119171 | Solid Tumor Cancer | Phase 1 | Completed | - | United States, Texas ... More >> GSK Investigational Site San Antonio, Texas, United States, 78229 Less << |
NCT00089973 | Neoplasms, Breast | PHASE2 | COMPLETED | 2006-08-25 | GSK Investigational Site, Jack... More >>sonville, Florida, 32224, United States|GSK Investigational Site, Indianapolis, Indiana, 46202, United States|GSK Investigational Site, Chapel Hill, North Carolina, 27599, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15213, United States|GSK Investigational Site, Bruxelles, 1000, Belgium|GSK Investigational Site, Bandar Tun Razak, Cheras, 56000, Malaysia|GSK Investigational Site, Bandar Tun Razak, Cheras, 59100, Malaysia|GSK Investigational Site, Singapore, 119074, Singapore|GSK Investigational Site, Singapore, 169610, Singapore|GSK Investigational Site, Southampton, Hampshire, SO16 6YD, United Kingdom|GSK Investigational Site, Manchester, Lancashire, M20 4BX, United Kingdom|GSK Investigational Site, Newcastle Upon Tyne, Northumberland, NE4 6BE, United Kingdom|GSK Investigational Site, London, W12 0NN, United Kingdom Less << |
NCT00354250 | Recurrent Renal Cell Cancer ... More >> Stage III Renal Cell Cancer Stage IV Renal Cell Cancer Less << | Phase 2 | Completed | - | United States, Illinois ... More >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 Less << |
Tags: Ispinesib | SB-715992 | SB715992 | SB 715992 | Kinesin | Apoptosis | kinesin spindle protein | KSP Inhibitor | 336113-53-2
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL